Skip to main content
SpringerLink
Log in

(Sogenannte) Atypische Neuroleptika (Antipsychotika)

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 39 Accesses

Zusammenfassung

Die Gruppe der sogenannten atypischen Antipsychotika ist pharmakologisch und klinisch heterogen. Es existiert kein verbindlicher Konsens darüber, wann ein Antipsychotikum als „atypisch“ zu kennzeichnen ist (Meltzer 1991). Letztlich umschreibt die Atypika-Definition klinisch festgestellte Besonderheiten der „Muttersubstanz“ Clozapin im Vergleich zu typischen Neuroleptika. Hierbei wurde in der Vergangenheit zunächst auf das Fehlen signifikanter extrapyramidalmotorischer Nebenwirkungen bei Gabe einer antipsychotisch wirksamen Dosis abgehoben, weiterhin auf das Fehlen von Spätdyskinesien und -dystonien. Im Gefolge der wegweisenden Studie von Kane et al. (1988) stand danach im Mittelpunkt des klinischen Interesses die Möglichkeit, mit atypischen Antipsychotika die als „schizophrenes Negativsyndrom“ (Andreasen 1982) zusammengefaßte Symptomgruppe besser als mit typischen Neuroleptika beeinflussen zu können (siehe Exkurs: Atypische Eigenschaften klassischer Substanzen).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788

    PubMed  CAS  Google Scholar 

  • Gallhofer B, Bauer U, Gruppe H, Krieger S, Lis S (1996) First episode schizophrenia: the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 55 [Suppl B]: 16–24

    Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Melzer HJ, Clozaril Collaborative Study Group (1988) Clozapin for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796

    PubMed  CAS  Google Scholar 

  • Meltzer HY (1991) The mechanism of action of novel atypic antipsychotic drugs. J Schizophr Bull 17: 263–287

    CAS  Google Scholar 

  • Meyer-Lindenberg A, Gruppe H, Bauer U, Krieger S, Lis S, Gallhofer B (1997) Improvement of cognitive functioning in schizophrenic patients receiving zotepine or clozapine: results of a double-blind trial. Pharmacopsychiatry 30: 35–42

    PubMed  CAS  Google Scholar 

  • Müller WE, Tuschl R, Gietzen K (1995) Therapeutische und unerwünschte Wirkungen von Neuroleptika — die Bedeutung von Rezeptorprofilen. Zotepin im Vergleich zu Risperidon, Clozapin und Haloperidol. Psychopharmako-therapie 2: 148–153

    Google Scholar 

  • Roth BL, Meltzer HY (1995) The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology. The fourth generation of progress. Raven Press, New York, pp 1215–1227

    Google Scholar 

Literatur

  • Ackenheil M (1989) Clozapine — pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99: S32–S37

    PubMed  Google Scholar 

  • Alfredsson G, Bjerkenstedt L, Edman G, Härnryd C, Oxenstierna G, Sedvall G, Wiesel F-A (1984) Relationships between drug concentrations in serum and CSF, clinical effects and mono-aminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatr Scand 69: 49–74

    Google Scholar 

  • Anderson CB, True JE, Ereshefsky L, Miller AL, Peters BL, Velligan DI (1993) Risperidone dose, plasma levels and response. Meeting of the American Psychiatric Association, San Francisco

    Google Scholar 

  • Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindstrom L, De La Rubia IR, Ramos S, Benitez J (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38: 471–473

    PubMed  CAS  Google Scholar 

  • Beuzen JN (1997) Olanzapine: initiating and maintaining treatment: clinical directions for maximizing re-integration. 6th World Congress of Biological Psychiatry, Nice

    Google Scholar 

  • Byerly MJ, Devane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16: 177–187

    PubMed  CAS  Google Scholar 

  • Centorrino F, Baldessarini RJ, Kando JK, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG (1994) Serum concentrations of clozapine and its major metabolites: effects of cotreat-ment with fluoxetine or valproate. Am J Psychiatry 151: 123–125

    PubMed  CAS  Google Scholar 

  • Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 34: 445–449

    PubMed  CAS  Google Scholar 

  • Choc M, Lehr R, Hsuan F, Honigfeld G, Smith H, Borison R, Volavka J (1987) Multiple dose pharmacokinetics of clozapine in patients. Pharm Res 4: 402–405

    PubMed  CAS  Google Scholar 

  • Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hir-Schowitz J, Wagner R (1990) Single-vs. multiple dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 7: 347–351

    PubMed  CAS  Google Scholar 

  • Dahl M-L, Llerena A, Bondesson U, Lindstrom L, Bertilsson L (1994) Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 37: 71–74

    PubMed  CAS  Google Scholar 

  • Dufour A, Desanti C (1989) Pharmacokinetics and mechanism of amisulpride. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Francaise, Paris, pp 43–51

    Google Scholar 

  • Dunn CJ, Fitton A (1996) Sertindole. CNS Drugs 5: 224–230

    CAS  Google Scholar 

  • Ereshefsky L, Anderson C, True J, Saklad S, Riesen-Man C, Toney G, Miller A (1993) Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy 13: 292

    Google Scholar 

  • Fischer V, Vogels B, Maurer G, Tynes RE (1992) The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260: 1355–1360

    PubMed  CAS  Google Scholar 

  • Fitton A, Heel RC (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722–747

    PubMed  CAS  Google Scholar 

  • Gerson SL, Arce C, Meltzer HY (1994) N-des-methylclozapin: a clozapine metabolite that supresses haemopoiesis. Br J Haematol 86: 555–561

    PubMed  CAS  Google Scholar 

  • Grant S, Fitton A (1994) Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48: 253–273

    PubMed  CAS  Google Scholar 

  • Grünberger J, Saletu B, Linzmayer L, Stoehr H (1989) Determination of pharmacokinetics and pharmacodynamics of amisulpride by pharmaco-EEG and psychometry. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Francaise, Paris, pp 37–42

    Google Scholar 

  • Haring C, Fleischhacker W, Schett P, Humpel C, Barnes C, Saria A (1990) Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 147: 1471–1475

    PubMed  CAS  Google Scholar 

  • Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer H (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13: 383–390

    PubMed  CAS  Google Scholar 

  • Heipertz R, Pilz H, Beckers W (1977) Serum concentrations of clozapine determined by nitrogen selective gas chromatography. Arch Toxicol 37: 313–318

    PubMed  CAS  Google Scholar 

  • Heykants J, Huang ML, Mannens G, Meuldermans W, Snoek E, van Beijsterveldt L, van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55: 13–17

    PubMed  Google Scholar 

  • Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14: 279–281

    PubMed  CAS  Google Scholar 

  • Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylic Z, Visscher HW, Jonkman JHG (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactine response in healthy subjects. Clin Pharmacol Ther 54: 257–268

    PubMed  CAS  Google Scholar 

  • Jann M, Grimsley S, Gray E, Chang W (1993) Pharmakokinetics and pharmakodynamics of clozapine. Clin Pharmakokinet 24: 161–176

    CAS  Google Scholar 

  • Jeppesen U, Loft S, Poulsen HE, Brosen K (1996) A fluvoxamine-caffeine interaction study. Pharmacogenentics 6: 213–222

    CAS  Google Scholar 

  • Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and Carbamazepin induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368–374

    PubMed  CAS  Google Scholar 

  • Kondo T, Otani K, Lshida M, Tanaka O, Kaneko S, Fukushima Y (1994) Adverse effects of zo-tepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 16: 120–124

    PubMed  CAS  Google Scholar 

  • Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179–182

    PubMed  CAS  Google Scholar 

  • Kuoppamäki M, Syvälahti E, Hietala J (1993) Clozapine and N-desmethylclozapine are potent S-HT1c, receptor antagonists. Eur J Pharmacol 245: 179–182

    PubMed  Google Scholar 

  • Larsen F, Hefting NR, Priskorn M, Mustafa MS, Oosterhuis B, Jonkman JHG (1996) Pharmacokinetics of sertindole in relation to CYP2D6 and CYP2C19 polymorphism and CYP3A4-activity in healthy volunteers. 3rd Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem

    Google Scholar 

  • Lilly E and Company A (1996) Zyprexa (Olanzapin) Product monograph, pp 1–87

    Google Scholar 

  • Lilly Research Laboratories (1996) Olanzapin: clinical studies — pharmacology. Eli Lilly and Company, Indianapolis (data on file)

    Google Scholar 

  • Lundbeck Ltd (1995) Sertindole: summary of clinical pharmacology. Lundbeck Ltd, Copenhagen (data on file)

    Google Scholar 

  • Lundbeck Ltd (1996) Sertindole. Product monograph, pp 3–56

    Google Scholar 

  • Luo H, Mckay G, Midha KK (1994) Identification of clozapine N-glucuronide in the urine of patients treated with clozapine using electro-spray mass spectrometry. Biol Mass Spectrm 23: 147–148

    CAS  Google Scholar 

  • Mannens G, Huang ML, Meuldermans W, Hen-Drickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dis 21: 1134–1141

    CAS  Google Scholar 

  • Mannens G, Meuldermans W, Huang ML, Snoeck E, Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 114: 566–572

    PubMed  CAS  Google Scholar 

  • Meltzer HY (1995a) Atypical antipsychotic drugs. In: Bloom F, Kupfer D (eds) Psychopharma-cology: the fourth generation of progress. Raven Press, New York, pp 1277–1285

    Google Scholar 

  • Meltzer HY (1995b) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3: 64–75

    PubMed  CAS  Google Scholar 

  • Miller D, Fleming F, Holman T, Perry P (1994) Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 55: 117–121

    PubMed  Google Scholar 

  • Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2: 281–293

    Google Scholar 

  • Noda K, Suzuki A, Okui H, Noguchi H, Nishiura M, Nishiura N (1979) Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylami-noethoxy)-dibenzo (b,f) thiepine (zotepine) in rat, mouse, dog and man. Arzneimittelfor-schung/Drug Res 29: 1595–2000

    CAS  Google Scholar 

  • O’Connor S, Brown R (1982) The pharmacology of sulpiride — a dopamine receptor antagonist. Gen Pharmacol 13: 185–193

    PubMed  Google Scholar 

  • Otani K (1992) Steady state serum kinetics of zotepine. Hum Psychopharmacol 7: 331–336

    Google Scholar 

  • Ott C (1992) Zotepin — ein Neuroleptikum mit neuartigem Wirkmechanismus. Fundam Psychiatr 6: 216–224

    Google Scholar 

  • Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231–235

    PubMed  CAS  Google Scholar 

  • Piscitelli SC, Frazier JA, Mckenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL (1994) Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 55: 94–97

    PubMed  Google Scholar 

  • Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Ju Y (1994) Plasma clozapine concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiatry 55: 133–138

    PubMed  Google Scholar 

  • Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA (1996a) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41: 181–186

    PubMed  CAS  Google Scholar 

  • Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson S, Hamman MA, Wrighton SA (1996b) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276: 658–666

    PubMed  CAS  Google Scholar 

  • Roszinsky-Köcher G, Dulz B (1996) Zotepin — ein atypisches Antipsychotikum. Fundam Psychiatr 10: 40–46

    Google Scholar 

  • Saletu B, Grünberger J, Anderer P, Chwatal K (1991) Zur Beziehung zwischen Blutspiegeln und mittels quantitativem EEG und Psycho-metrie gemessenen pharmakodynamischen Veränderungen nach Zotepin. Fortschr Neural Psychiat 59: 45–55

    Google Scholar 

  • Schulz E, Fleischhaker C, Remschmidt H (1995) Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiat 28: 20–25

    CAS  Google Scholar 

  • Snoeck E, Van Peer A, Sack M, Horton M, Manners G, Woestenborghs R, Meibach R, Heykants J (1995) Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 122: 223–229

    PubMed  CAS  Google Scholar 

  • Tzeng TB, Stamm G, Chu SY (1994) Sensitive method for the assay of sertindole in plasma by high performance liquid chromatography and fluorometric detection. J Chromatogr B Biomed Appl 661: 299–306

    PubMed  CAS  Google Scholar 

  • van Beijsterveldt L, Geerts RJF, Leysen J, Megens A, van den Eynde H, Meuldermans W, Heykants J (1994) The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114: 53–62

    PubMed  Google Scholar 

  • Wiesel F, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17: 385–391

    PubMed  CAS  Google Scholar 

Literatur

  • Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central anti-adrenergic actions contribute to the atypical properties of clozapine. Br J Psychiatry 160 [Suppl 17]: 12–16

    Google Scholar 

  • Barnas C, Stuppäck CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. Haloperidol. Int Clin Psychopharmacol 7: 23–27

    PubMed  CAS  Google Scholar 

  • Barnes TRE, Mcphillips MA (1996) Antipsychotic-induced extrapyramidal symptoms — role of anticholinergic treatment. CNS Drugs 6: 315–330

    CAS  Google Scholar 

  • Baymaster TP, Calligaro DO, Falcone JF (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 14: 87–96

    Google Scholar 

  • Bischoff S, Delini-Stula A, Maitre L (1985) Blockade der Dopamin-Rezeptoren im Hippokampus als Indikator antipsychotischer Wirksamkeit. Korrelationen zwischen neuro-chemischen und psycho-pharmakologischen Wirkungen von Neuroleptika. In: Pflug B, Foerster K, Straube E (Hrsg) Perspektiven der Schizophrenie-Forschung. Fischer, Stuttgart, S 87–103

    Google Scholar 

  • Bunney BS (1992) Clozapine: a hypothesised mechanism for its unique clinical profile. Br J Psychiatry 160 [Suppl 17]: 17–21

    Google Scholar 

  • Cohen BM, Lipinski JF (1986a) Treatment of acute psychosis with non-neuroleptic agents. Psychosomatics [Suppl 27]: 7–16

    Google Scholar 

  • Cohen BM, Lipinski JF (1986b) In vivo potencies of antipsychotic drugs in blocking α-1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci 39: 2571–2580

    PubMed  CAS  Google Scholar 

  • Coukell BM, Spencer CM, Benfield P (1996) Amisulpride. CNS Drugs 6: 237–256

    CAS  Google Scholar 

  • Coward DM (1992) General pharmacology of clozapine. Br J Psychiatry 160 [Suppl 17]: 5–11

    Google Scholar 

  • Ereshefsky L (1995) Ein pharmakodynamisches und pathophysiologisches Modell der medikamentösen antipsychotischen Therapie der Schizophrenie. In: Gerlach J (Hrsg) Schizophrenie: Dopaminrezeptoren und Neuroleptika. Springer, Berlin Heidelberg New York Tokyo, S 149–184

    Google Scholar 

  • Ereshefsky L, Lacombe S (1993) Pharmacological profile of risperidone. Can J Psychiat 38 [Suppl 3]: 80–88

    Google Scholar 

  • Farde L, Nordström AL, Wiesel FA, Pauli S, Hall-Din C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538–544

    PubMed  CAS  Google Scholar 

  • Gerlach J (1995) D1-und kombinierte D1-/D2-Rezeptorblockade bei Schizophrenic In: Gerlach J (Hrsg) Schizophrenie: Dopaminrezeptoren und Neuroleptika. Springer, Berlin Heidelberg New York Tokyo, S 138–148

    Google Scholar 

  • Gerlach J, Hansen L (1992) Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry 160 [Suppl 17]: 34–37

    Google Scholar 

  • Hippius H (1995) Sulpirid. Rückblick und Perspektiven. Psychopharmakotherapie 2: 102–109

    Google Scholar 

  • Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. TiPS 14: 233–236

    PubMed  CAS  Google Scholar 

  • Hyttel J, Nielsen JB, Nowak G (1992) The acute effects of sertindole on brain 5-HT2, D2 and α1 receptors. J Neural Transm 89: 61–69

    CAS  Google Scholar 

  • Kane JM (1992) Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 160 [Suppl 17]: 41–45

    Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    PubMed  CAS  Google Scholar 

  • Kennett GA, Pittaway K, Blackburn TP (1994) Evidence that 5HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology 114: 90–96

    PubMed  CAS  Google Scholar 

  • Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990) Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand 82 [Suppl 358]: 27–36

    Google Scholar 

  • Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112: S40–S54

    PubMed  CAS  Google Scholar 

  • Livingstone MG (1994) Risperidone. Lancet 343: 457–460

    Google Scholar 

  • Markstein R (1994a) Bedeutung neuer Dopaminrezeptoren für die Wirkung von Clozapin. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums: Neuere Aspekte der klinischen Praxis. Springer, Berlin Heidelberg New York Tokyo, S 5–15

    Google Scholar 

  • Markstein R (1994b) Die Rolle von Dopamin bei der Behandlung der Schizophrenie mit Clozapin. Sandorama 4: 3–11

    Google Scholar 

  • Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287

    PubMed  CAS  Google Scholar 

  • Meltzer HY (1992) The importance of serotonin-dopamin interactions in the action of clozapine. Br J Psychiatry 160 [Suppl 17]: 22–29

    Google Scholar 

  • Möller HJ (1995) Neuere Aspekte in der Diagnostik und Behandlung der Negativsymptomatik schizophrener Patienten. In: Hinterhuber H, Fleischhacker WW, Meise U (Hrsg) Die Behandlung der Schizophrenien — State of the Art. Verlag Integrative Psychiatrie, Innsbruck Wien, S 197–212

    Google Scholar 

  • Müller WE (1990) Pharmakologische Aspekte der Neuroleptikawirkung. In: Heinrich K (Hrsg) Leitlinien neuroleptischer Therapie. Springer, Berlin Heidelberg New York Tokyo, S 3–23

    Google Scholar 

  • Müller WE (1992) Pharmakologie der Neuroleptika unter besonderer Berücksichtigung des Remoxiprids. Krankenhauspsychiatrie 3 [Sonderheft 1]: 14–22

    Google Scholar 

  • Müller WE, Tuschl R, Gietzen K (1995) Therapeutische und unerwünschte Wirkungen von Neuroleptika — die Bedeutung von Rezeptorprofilen. Psychopharmakotherapie 2: 148–153

    Google Scholar 

  • Müller-Spahn F, Dieterle D, Ackenheil M (1991) Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik. Ergebnisse einer offenen und einer dop-pelblind-kontrollierten Studie. Fortschr Neurol Psychiatr 59 [Sonderheft 1]: 30–35

    PubMed  Google Scholar 

  • Nutt DJ (1994) Putting the ‘A’ in atypical. J Psychopharmacol 8: 193–195

    PubMed  CAS  Google Scholar 

  • Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B (1993) 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 110: 265–272

    PubMed  CAS  Google Scholar 

  • Ögren SO, Florvall L, Hall H, Magnusson O, Ängeby-Möller K (1990) Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 82 [Suppl 358]: 21–26

    Google Scholar 

  • Ögren SO, Rosen L, Fuxe K (1994) The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of D2 receptors. Neuroscience 61: 269–283

    PubMed  Google Scholar 

  • Pickar D (1995) Prospects for pharmacotherapy of schizophrenia. Lancet 345: 557–562

    PubMed  CAS  Google Scholar 

  • Reynolds PC (1996) The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs 51: 7–11

    PubMed  CAS  Google Scholar 

  • Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 43: 331–336

    Google Scholar 

  • Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol 112: 285–292

    CAS  Google Scholar 

  • Schwartz JC, Levesque D, Martres MP, Sokoloff P (1993) Dopamine D3-receptor: basic and clinical aspects. Clin Neuropharmacol 16: 295–314

    PubMed  CAS  Google Scholar 

  • Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152

    PubMed  CAS  Google Scholar 

  • Sleight AJ, Koek W, Bigg DCH (1993) Binding of antipsychotic drugs at α1A-and α1B-adreno-ceptors: risperidone is selective for the α1B-adrenoceptors. Eur J Pharmacol 238: 407–410

    PubMed  CAS  Google Scholar 

  • Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61

    PubMed  CAS  Google Scholar 

  • Sokoloff P, Giros B, Martres MP, Bouthenet M-L, Schwartz C-J (1990) Molecular cloning and characterization of novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151

    PubMed  CAS  Google Scholar 

  • Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2-receptors. J Pharmacol Exp Ther 266: 1374–1384

    PubMed  CAS  Google Scholar 

  • Sunahara RK, Seeman P, van Tol HHM, Niznik HB (1993) Dopamine receptors and antipsychotic drug response. Br J Psychiatry 163 [Suppl 22]: 31–38

    Google Scholar 

  • van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614

    PubMed  Google Scholar 

  • Wang RY, Ashby CR Jr, Zhang JY (1996) Modulation of the A10 dopamine system: electrophysiological studies of the role of 5-HT3-like receptors. Behav Brain Res 73: 7–10

    PubMed  CAS  Google Scholar 

  • Wolfersdorf M, König F, Straub R (1993) Zotepin und Antidepressiva in der medikamentösen Behandlung der wahnhaften Depression. Psychiatr Praxis 20 [Sonderheft]: 55–58

    Google Scholar 

Literatur

  • Ackenheil M, Braeu H (1976) Antipsychotische Wirksamkeit im Verhältnis zum Plasmaspiegel von Clozapin. Arzneimittelforschung/Drug Res 26: 1156–1158

    CAS  Google Scholar 

  • Alvir JMJ, Liebermann JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapin-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329:162–167

    PubMed  CAS  Google Scholar 

  • Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (1977) Agranulocytosis in patients treated with clozapine, a study of the Finnish epidemic. Acta Psychiatr Scand 56: 241–248

    PubMed  CAS  Google Scholar 

  • Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmakopsychiat 4: 201–211

    Google Scholar 

  • Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324: 746–754

    PubMed  CAS  Google Scholar 

  • Bonucelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A (1994) Clozapine in Huntington’s chorea. Neurology 44: 821–823

    Google Scholar 

  • Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20–26

    PubMed  CAS  Google Scholar 

  • Buchanan RW (1995) Clozapine: efficacy and safety. Schizophr Bull 21: 579–591

    PubMed  CAS  Google Scholar 

  • Buchanan RW, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36: 717–725

    PubMed  CAS  Google Scholar 

  • Centorrino F, Baldessarini RJ, Frankenburg FR, Jando J, Volpicelli SA, Flood JG (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153: 820–822

    PubMed  CAS  Google Scholar 

  • Claghorn I, Honigfeld G, Abuzzahab FS, Wang R, Steinbrook R, Tuason V, Klerman G (1987) The risk and benefits of clozapine versus chlorpro-mazine. J Clin Psychopharmacol 7: 377–384

    PubMed  CAS  Google Scholar 

  • Classen W, Laux G (1988) Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol or clozapine. Pharmacopsychiat 21: 295–297

    CAS  Google Scholar 

  • Clozapine Study Group (1993) The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 163: 150–154

    Google Scholar 

  • Cohen BM, Keck PE, Satlin A, Cole JO (1991) Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 29: 1215–1219

    PubMed  CAS  Google Scholar 

  • Davies LM, Drummond MF (1993) Assessment of coss and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162: 38–42

    PubMed  CAS  Google Scholar 

  • Ereshefsky L, Watanabe MD, Tran-Johnson TK (1989) Clozapine an atypical antipsychotic agent. Clin Pharmacol 8: 691–709

    CAS  Google Scholar 

  • Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538–544

    PubMed  CAS  Google Scholar 

  • Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 40: 722–747

    PubMed  CAS  Google Scholar 

  • Gaebel W, Klimke A, Klieser E (1994) Kombination von Clozapin mit anderen Psychopharmaka. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin Heidelberg New York Tokyo, S 43–58

    Google Scholar 

  • Gerlach J, Jorgensen EO, Peacock L (1989) Long-term experience with clozapine in Denmark: research and clinical practice. Psychopharmacol 99: S92–S96

    Google Scholar 

  • Goldberg TE, Greenberg RD, Griffin SF, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162: 43–48

    PubMed  CAS  Google Scholar 

  • Grohmann R, Schmidt LG, Spiess-Kiefer C, Rüther E (1989) Agranulocytosis and significant leu-copenia with neuroleptic drugs: results from the AMÜP program. Psychopharmacology 99: S109–S112

    PubMed  Google Scholar 

  • Hagger C, Buckley P, Kenny JT, Friedman L, Uubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702–712

    PubMed  CAS  Google Scholar 

  • Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14: 279–281

    PubMed  CAS  Google Scholar 

  • Hippius H (1989) The history of clozapine. Psychopharmacol 99: 53–55

    Google Scholar 

  • Hirsch SR, Puri BK (1993) Clozapine: progress in treating refractory schizophrenia. Br Med J 306: 1427–1428

    CAS  Google Scholar 

  • Jonsson D, Walinder J (1995) Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 92: 199–201

    PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlor-promazine. Arch Gen Psychiatry 45: 789–796

    PubMed  CAS  Google Scholar 

  • Klimke A, Klieser E (1995) Das atypische Neuro-leptikum (Leponex-R) — aktueller Kenntnisstand und neuere klinische Aspekte. Fortschr Neurol Psychiat 63: 173–193

    PubMed  CAS  Google Scholar 

  • Klimke A, Klieser E, Lemmer W (1995) Clozapin in der Rezidivprophylaxe. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin Heidelberg New York Tokyo, S 81–92

    Google Scholar 

  • Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152: 179–182

    PubMed  CAS  Google Scholar 

  • Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158: 503–510

    PubMed  CAS  Google Scholar 

  • Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia response to treatment and predictors of outcome. Am J Psychiatry 151: 1744–1752

    PubMed  CAS  Google Scholar 

  • Lindström LH (1988) The effect of long-term treatment with clozapine in schizophrenia a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77: 524–529

    PubMed  Google Scholar 

  • Mallya AR, Roos PD, Roebuck-Colgan K (1992) Restraint, seclusion and clozapine. J Clin Psychiatry 53: 395–397

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Okayli G (1995) Reduction of suici-dality during clozapine treatment of neurolep-tic-resistant schizophrenia: impact on risk-benefit assessment. Am I Psychiatry 152: 183–190

    CAS  Google Scholar 

  • Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry 8: 892–897

    Google Scholar 

  • Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B (1993) Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 150: 1630–1638

    PubMed  CAS  Google Scholar 

  • Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10 [Suppl 3]: 133–138

    PubMed  Google Scholar 

  • Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: S73–S76

    PubMed  Google Scholar 

  • Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 [Suppl 17]: 54–59

    Google Scholar 

  • Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D1 D2 and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444–1449

    PubMed  Google Scholar 

  • Nöthen MM, Rietschel M, Erdmann J, OBerländer H, Möller HJ, Naber D, Propping P (1995) Genetic variation of the 5-HT2A-receptor and response to clozapine. Lancet 346: 908–909

    PubMed  Google Scholar 

  • Pajonk FG (1997) Klinische Erfahrungen mit neuen Neuroleptika — Alternativen zu Clozapin. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Neue klinische Ergebnisse. Springer, Berlin Heidelberg New York Tokyo (im Druck)

    Google Scholar 

  • Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73: 295–297

    PubMed  CAS  Google Scholar 

  • Peacock K, Gerlach J (1994) Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 55: 44–49

    PubMed  CAS  Google Scholar 

  • Perry PJ, Miller DD, Arndt SV et al. (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231–235

    PubMed  CAS  Google Scholar 

  • Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH (1992) Clinical and biological response to clozapine in patients with schizophrenia crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345–353

    PubMed  CAS  Google Scholar 

  • Povlsen UJ, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71: 176–185

    Google Scholar 

  • Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J (1994) Allelic variaton in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 51: 912–917

    PubMed  CAS  Google Scholar 

  • Reid WH, Mason M, Toprac M (1994) Savings in hospital bed-days related to treatment with clozapine. Hosp Commun Psychiatry 45: 261–264

    CAS  Google Scholar 

  • Rietschel M, Naber D, Oberländer H, Holzbach R, Fimmers R, Eggermann K, Möller H-J, Propping P, Nöthen MM (1996) Efficacy and side-effects of clozapine testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 15: 491–496

    PubMed  CAS  Google Scholar 

  • Safferman A, Lieberman JA, Kane JM, Szymansky S, Kinon B (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17: 247–261

    PubMed  CAS  Google Scholar 

  • Safferman AZ, Lieberman JA, Pollack S, Kane JM (1993) Akathisia and clozapine treatment. J Clin Psychopharmacol 13: 286–287

    PubMed  CAS  Google Scholar 

  • Sassim N, Grohmann R (1988) Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiat 21: 306–307

    CAS  Google Scholar 

  • Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pahrmakologischen und klinischen Befunden mit Clozapin). Pharmakopsychiat 4: 182–191

    CAS  Google Scholar 

  • Stille G, Fischer-Cornelssen K (1988) Die Entwicklung von Clozapin (Leponex) — ein Mysterium? In: Linde OK (Hrsg) Pharmako-Psychiatrie im Wandel der Zeit: Erlebnisse und Ergebnisse. Tilia-Verlag, Klingenmünster, S 339–348

    Google Scholar 

  • Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao X-M (1994) Clozapine in tardive dyskinesia observations from human and animal model studies. J Clin Psychiatry 55: S102–S106

    Google Scholar 

  • Treves IA, Neufeld MY (1996) EEG abnormalities in clozapine treated schizophrenic patients. Eur Neuropsychopharmacol 6: 93–94

    PubMed  CAS  Google Scholar 

  • Van Tol HHM, Bunzow JR, Guan H-C, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614

    PubMed  Google Scholar 

  • Wagstaff AJ, Bryson HM (1995) Clozapine — a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 4: 370–400

    CAS  Google Scholar 

  • Wolters ECH, Hurwitz TA, Mak E (1990) Clozapine in the treatment of Parkinsonian patients with dopaminomimetic psychosis. Neurology 40: 832–834

    PubMed  CAS  Google Scholar 

Literatur

  • Borison RL (1991) Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Aug 1991. Janssen Clinical Research Report no.: RIS-USA-9001

    Google Scholar 

  • Borison RL, Pathiraja AP, Diamond BI, Meibach RC (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28: 213–218

    PubMed  CAS  Google Scholar 

  • Castelao JF, Ferreira L, Gelders YG, Heylen SL (1989) The efficacy of the D2 and 5-HT2 antagonist risperidone (R64 776) in the treatment of chronic psychosis: an open dose finding study. Schizophr Res 2: 411–415

    PubMed  CAS  Google Scholar 

  • Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) The extrapyramidal symptom rating scale. Can J Neurol Sci 7: 233

    Google Scholar 

  • Chouinard G, Jones B, Remington G (1993) A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40

    PubMed  CAS  Google Scholar 

  • Claus A, Bollen J, de Cuyper H, Eneman M, Mal-Froid M, Peuskens J, Heylen S (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand 8S: 295–305

    Google Scholar 

  • Coppen A, Prange AJ Jr, Whybrow PC (1969) Methysergide in mania. A controlled trial. Lancet ii: 338–340

    Google Scholar 

  • Curtis VA, Kerwin RW (1995) A risk-benefit assessment of risperidone in schizophrenia. Drug Safety 12: 139–145

    PubMed  CAS  Google Scholar 

  • Davts JM, Janicak PG (1996) Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Annals 26(2): 78–87

    Google Scholar 

  • Delisi LE, Neckers LM, Weinberger DR, Wyatt RJ (1981) Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 38: 647–650

    PubMed  CAS  Google Scholar 

  • Grant S, Fitton A (1994) Risperidone. A review of ist pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 48: 253–274

    PubMed  CAS  Google Scholar 

  • Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H (1994) Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind randomised trial. Prog Neuropsychopharmacol Biol Psychiatry 18: 129–137

    PubMed  CAS  Google Scholar 

  • Hoyberg OJ, Fensbo J, Remvig J (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 88: 395–402

    PubMed  CAS  Google Scholar 

  • Janssen Research Foundation (ed) (1991) A randomized, double-blind, multicenter trial of risperidone in the treatment of chronic schizophrenia. Clinical research report (RIS-Int-3). November 1991. Janssen, Piscataway New Jersey

    Google Scholar 

  • Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S (1995) The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57: 103–107

    Google Scholar 

  • Kay SR, Opler LA, Fiszbein A (1987) Positive and negative syndrome scale (PANSS). Rating manual. Social and behavioral documents. San Rafael, CA

    Google Scholar 

  • Livingstone ME (1994) Risperidone. Lancet 343: 457–460

    Google Scholar 

  • Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835

    PubMed  CAS  Google Scholar 

  • Mertens C (1992) Risperidone treatment in psychotic patients: a combined analysis of the data from three open long term trials. Feb 1992. Janssen Clinical Research Report no.: RIS-HOL-9002

    Google Scholar 

  • Mesotten F (1991) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double blind study. Aug 1991. Janssen Clinical Research Report no.: RIS-Bel-7

    Google Scholar 

  • Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R64 766) in psychotic patients. Psychopharmacology 99: 445–449

    PubMed  CAS  Google Scholar 

  • Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C (1986) Decreased serotonin S2 and increased D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407–1414

    PubMed  CAS  Google Scholar 

  • Möller H-J (1993) Extrapyramidalmotorische Begleitwirkungen von Neuroleptika unter besonderer Berücksichtigung von Risperidon. In: Platz T (Hrsg) Brennpunkte der Schizophrenie. Gesellschaft — Angehörige — Therapie. Aktuelle Probleme der Schizophrenie, Bd 4. Springer, Wien New York, S 333–345

    Google Scholar 

  • Möller H-J (1995) Extrapyramidal side effects of neuroleptic medication: focus on risperidone. In: Brunello N, Racagni G, Langer SZ, Mend-Lewicz J (eds) Critical issues in the treatment of schizophrenia, vol 10. Int Acad Biomed Drug Res 10: 142–151

    Google Scholar 

  • Möller H-J, Dietzfelbinger T, Jansen M (1989) German pilot study of risperidone. Preliminary clinical results and brain mapping findings. In: Ayd FJ (ed) 30 Years Janssen research in psychiatry. Ayd Medical Communications, Baltimore, pp 108–114

    Google Scholar 

  • Möller H-J, Pelzer E, Kissling W, Riehl T, Wernicke T (1991) Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry 24: 185–189

    PubMed  Google Scholar 

  • Möller H-J, Müller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenia patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45–49

    PubMed  Google Scholar 

  • Möller H-J, Gagiano G, Aldington DE, Knorring L V, Torres-Planck F, Gaussares C (1997) Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. J Clin Psychiatry (submitted)

    Google Scholar 

  • Niemegeers CJE, Awouters F, Janssen PAJ (1990) Pharmakologie der Neuroleptika und relevante Mechanismen zur Behandlung von Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 185–197

    Google Scholar 

  • Peuskens J (Risperidone Study Group) (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726

    Google Scholar 

  • Remvig J (1991) Risperidone and perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations: a multicentre double-blind parallel group comparative study. Nov 1991. Janssen Clinical Research Report no.: RIS-INT-7

    Google Scholar 

  • Tatossian A (1991) Comparative double blind trial of the efficacy of risperidone, haloperidol and levomepromazine (methotrimeprazine) in patients with an acute exacerbation of schizophrenia presenting psychotic anxiety symptoms. Nov 1991. Janssen Clinical Research Report no.: RIS-FRA-9003

    Google Scholar 

  • Umbricht D, Kane JM (1995) Risperidone: efficacy and safety. Schizophr Bull 21: 593–606

    PubMed  CAS  Google Scholar 

  • Wolley DW, Shaw E (1954) A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci 40: 228–231

    Google Scholar 

Literatur

  • Achiron A, Zoldan YE (1990) Tardive dyskinesia induced by sulpiride. Clin Neuropharmacol 13: 248–252

    PubMed  CAS  Google Scholar 

  • Ackenheil M, Macher JP (1996) Selective versus non-selective neuroleptics: advantages and disadvantages. Eur Neuropsychopharmacol 6: S4-22

    Google Scholar 

  • Alberts JL, Francois F, Josserand F (1985) Etude des effects secondaires rapportés à l’occasion de traitements par dogmatil. Sem Hôp Paris 19: 1351–1357

    Google Scholar 

  • Alfredsson G, Bjerkenstedt L, Edman G (1984) Relationships between drug concentrations in serum and CSF, clinical effects and mono-aminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatr Scand 69 [Suppl 311]: 49–74

    Google Scholar 

  • Alfredsson G, Härnryd C, Wiesel F (1985) Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients-relationship to drug concentrations. Psychopharmacology 85: 8–13

    PubMed  CAS  Google Scholar 

  • Aylward M, Maddock J, Dewland P, Lewis P (1981) Sulpiride in depressive illness. Adv Biol Psychiatr 7: 154–165

    Google Scholar 

  • Benkert O, Holsboer F (1984) Effect of sulpiride in endogenous depression. Acta Psychiatr Scand 69 [Suppl 311]: 43–48

    Google Scholar 

  • Bischof S, Christen P, Vassout A (1988) Blockade of hippocampal dopamine receptors: a tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol 12: 445–467

    Google Scholar 

  • Boyer P, Lecrubier Y (1996) Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus ami-neptine. Eur Psychiatry 11 [Suppl 3]: 135s–140s

    Google Scholar 

  • Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72

    PubMed  CAS  Google Scholar 

  • Boyer P, Möller HJ, Fleurot O, Rein W, Prod-Aslp Study Group (1997) Improvement of acute exacerbations of schizophrenia with amisulpride; a comparison to haloperidol. Psychopharmacology (in press)

    Google Scholar 

  • Bratfos O, Haug J (1979) Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicenter study. Acta Psychiatr Scand 60: 1–9

    PubMed  CAS  Google Scholar 

  • Caley CF, Weber SS (1995) Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29: 152–160

    PubMed  CAS  Google Scholar 

  • Casey D, Gerlach J, Simmelsgaard H (1979) Sulpiride in tardive dyskinesia. Psychopharmacology 66: 73–77

    PubMed  CAS  Google Scholar 

  • Cassano G, Castrogiovanni P, Conti L, Bonollo L (1975) Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. Curr Ther Res 17: 189–201

    PubMed  CAS  Google Scholar 

  • Catapano F, Maj M, Grimaldi F, Ventra C, Kemali D (1992) Efficacy of low vs. high doses of levosulpiride on negative symptoms of schizophrenia. Pharmacopsychiat 25: 166

    CAS  Google Scholar 

  • Chivers JK, Gommeren W, Leysen JE (1988) Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 40: 415–421

    PubMed  CAS  Google Scholar 

  • Colonna L, Guerault E, Turjanski S (1997) Long-term study of amisulpride in the treatment of schizophrenia. Biol Psychiatry 42: 181S

    Google Scholar 

  • Costa E Silva JA (1989) Comparative double blind study of amisulpride versus haloperidol in the treatment of acute psychotic states. In: Borenstein P (ed) Amisulpride. Expansion Scientifique Française, Paris, pp 93–104

    Google Scholar 

  • Costa E Silva JA (1990) Traitement des dysthy-mies par de faibles doses d’amisulpride. Etude comparative amisulpride 50 mg/j versus placebo. Ann Psychiatr 5: 242–249

    Google Scholar 

  • Coukell AJ, Spencer CM, Benfield P (1996) Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6: 237–256

    CAS  Google Scholar 

  • Delcker A, Schoon ML, Oczkowski B, Gaertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients — results of a double-blind study. Pharmacopsychiat 23: 125–130

    CAS  Google Scholar 

  • Dreyfus JF (1985) Essai comparatif multicen-terique en double insu du dogmatil et de la chorpromazine dans le traitement de la psychose aigue. Sem Hôp Paris 61: 1322–1326

    Google Scholar 

  • Edwards J, Alexander J, Alexander M, Alexander MS, Gordon A, Zutchi T (1980) Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry 137: 522–529

    PubMed  CAS  Google Scholar 

  • Elizur A, Davidson S (1975) The evaluation of the anti-autistic activity of sulpiride. Curr Ther Res 18: 578–584

    PubMed  CAS  Google Scholar 

  • Favennec C, Rein W, Turjanski S (1996) The safety profile of amisulpride, an „atypical“ antipsychotic. Eur Neuropsychopharmacol 6: S4-111

    Google Scholar 

  • Fleurot O, Bech P, Turjanski S (1997) Amisulpride versus risperidone in the treatment of acute schizophrenia. Biol Psychiatry 42: 194S

    Google Scholar 

  • Freeman HL (1997) Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 12 [Suppl 2]: S11–S17

    PubMed  Google Scholar 

  • Gaultier M, Frejaville JP (1973) A propos de 20 surdosages en sulpiride. J Eur Toxicol 6: 42–44

    CAS  Google Scholar 

  • Gerlach J, Casey D (1984) Sulpiride in tardive dyskinesia. Acta Psychiatr Scand 69 [Suppl 311]: 93–102

    Google Scholar 

  • Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H (1985) Sulpiride and haloperidol in schizophrenia: a double blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry 147: 283–288

    PubMed  CAS  Google Scholar 

  • Grohmann R, Rüther E, Schmidt LG (Hrsg) (1994) Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Haase H, Floru L (1974) Klinisch-neuroleptische Untersuchungen des Sulpirid an akut erkrankten Schizophrenen. Int Pharmacopsychiat 9: 77–94

    CAS  Google Scholar 

  • Haggstrom J (1980) Sulpiride in tardive dyskinesia. Curr Ther Res 27: 164–169

    Google Scholar 

  • Härnryd C, Bjerkenstedt L, Björk K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA (1984a) Clinical evaluation of sulpiride in schizophrenic patients — a double blind comparison with chlorpromazine. Acta Psychiatr Scand 69 [Suppl 311]: 7–30

    Google Scholar 

  • Härnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel F (1984b) Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand 69 [Suppl 311]: 75–92

    Google Scholar 

  • Hofferberth B, Grotemeyer K (1985) Flunarizin und Sulpirid: Vergleich zweier gebräuchlicher Antivertiginosa bei vertebrobasilär bedingtem Schwindel. Nervenarzt 56: 553–559

    PubMed  CAS  Google Scholar 

  • Jenner P, Marsden C (1984) Multiple dopamine receptors in brain and the pharmacological action of substituted benzamide drugs. Acta Psychiatr Scand 69 [Suppl 311]: 109–124

    Google Scholar 

  • Johnson S, Johnson SN (1996) Sulpiride in somatoform disorders. Rev Contemp Pharmacother 7(6)

    Google Scholar 

  • Kaiya J, Takeda N (1990) Sulpiride in the treatment of delusional depression. J Clin Psychopharmacol 10: 147–148

    PubMed  CAS  Google Scholar 

  • Kaneko Y, Yamamoto Y, Hosaka H (1983) Intravenous administration of sulpiride and heat sensation on the body surface. Neuropsychobiology 9: 26–30

    PubMed  CAS  Google Scholar 

  • Kashihara K, Ishida K (1988) Neuroleptic malignant syndrome due to sulpiride. J Neurol Neurosurg Psychiatry 51: 109–110

    Google Scholar 

  • Keller K (1978) Die Behandlung psychogener Störungen und psychosomatischer Erkrankungen. Erfahrungen mit Sulpirid. ZFA 54: 892–899

    CAS  Google Scholar 

  • Kogeorgos J, Kanellos P, Michalakeas A, Ioannidis J (1995) Sulpiride and risperidone vs. „classical neuroleptics“ in schizophrenia: a follow-up study. Eur Neuropsychopharmacol 5: 335–336

    Google Scholar 

  • Köhler C, Ögren S, Fuxe K (1984) Studies on the mechanism of action of substituted benzami-de drugs. Acta Psychiatr Scand 69 [Suppl 311]: 125–138

    Google Scholar 

  • Lam S, Lam K, Lai C (1979) Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study. Gastroenterology 76: 315–322

    PubMed  CAS  Google Scholar 

  • Laljx G (1992) Remoxiprid — ein atypisches Neu-roleptikum der Benzamidgruppe. Fundam Psychiatr 6: 45–51

    Google Scholar 

  • Laux G, Broich K (1994) Sulpirid — ein atypisches Neurothymoleptikum. Fundam Psychiatr 8: 50–59

    Google Scholar 

  • Lecrubier Y, Boyer P, Turjanski S, Rein W (1997) Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord 43: 95–103

    PubMed  CAS  Google Scholar 

  • Lepola U, Koskinen T, Rimon R, Salo H, Gordin A (1989) Sulpiride and perphenazine in schizophrenia. Acta Psychiatr Scand 80: 92–96

    PubMed  CAS  Google Scholar 

  • Lewander T, Westerbergh SE, Morrison D (1990) Clinical profile of remoxipride — a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand 82 [Suppl 358]: 92–98

    Google Scholar 

  • Loo H, Poirier-Littre MF, Theron M, Rein W, Fleu-Rot O (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22

    PubMed  CAS  Google Scholar 

  • Margaret J, Herrmann P (1988) Die Benzamide — Entdeckung und Entwicklung in der Psychiatric In: Linde O (Hrsg) Pharmakopsychiatrie im Wandel der Zeit. Tilia, Klingenmünster, S 349–371

    Google Scholar 

  • Marks I (1980) Current therapy in gastric ulcer. Drugs 20: 283–299

    PubMed  CAS  Google Scholar 

  • Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loo H, Maziere B (1996) In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124: 154–158

    PubMed  CAS  Google Scholar 

  • Mauri MC, Leva P, Coppola MT, Altamura CA (1994) L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables. Prog Neuropsychopharmacol Biol Psychiatry 18: 355–356

    PubMed  CAS  Google Scholar 

  • Meyers C, Vrancks C, Elgen K (1985) Psychosomatic disorders in general practice: comparisons of treatment with flupenthixol, diazepam and sulpiride. Pharmatherapeutika 4: 244–250

    CAS  Google Scholar 

  • Mielke D, Gallant D, Roniger J, Kessler J, Kessler LR (1977) Sulpiride: evaluation of antipsychotic activity in schizophrenic patients. Dis Nerv Syst 38: 569–571

    PubMed  CAS  Google Scholar 

  • Miller L, Jankovic J (1990) Sulpiride-induced tardive dystonia. Mov Disord 5: 83–84

    PubMed  CAS  Google Scholar 

  • Möller HJ, van Praag HM, Auedembrinke B et al. (1994) Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 115: 221–228

    PubMed  Google Scholar 

  • Möller HJ, Boyer P, Fleurot O, Rein W (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132: 396–401

    PubMed  Google Scholar 

  • Munk-Andersen E, Behnke K, Heltberg J, Gerlach J, Nielsen H (1984) Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatr Scand 69 [Suppl 311]: 31–41

    Google Scholar 

  • Niskanen P, Tamminen T, Viukari M (1975) Sulpiride vs. amitriptyline in the treatment of depression. Curr Ther Res 17: 281–284

    PubMed  CAS  Google Scholar 

  • Paes DE Sousa M (1996) Amisulpride in dysthymia: results of a naturalistic study in general practice. Eur Psychiatry 11 [Suppl 3] 145s

    Google Scholar 

  • Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152: 130–133

    PubMed  CAS  Google Scholar 

  • Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride, an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. JPET 280: 73–82

    CAS  Google Scholar 

  • Peselow E, Stanley M (1982) Clinical trials of benzamides in psychiatry. Adv Biochem Psychopharmacol 35: 163–194

    PubMed  CAS  Google Scholar 

  • Pichot P, Boyer P (1988) Essai multicentrique contrôlé, en double insu, amisulpride (Solian® 50) contre Fluphénazine à faibles doses dans le traitement du syndrome déficitaire des schizophrénies chroniques. Ann Psychiatr 3: 312–320

    Google Scholar 

  • Rama Rao VA, Bailey J, Bishop M, Coppen A (1981) A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology 73: 77–80

    Google Scholar 

  • Rein W, Turjanski S (1997) Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12 [Suppl 2]: S19–S27

    PubMed  Google Scholar 

  • Reveley MA, Dursun SM, Andrews H (1996) A comparative trial use of sulpiride and risperidone in Huntington’s disease: a pilot study. J Psychopharmacol 10: 162–165

    PubMed  CAS  Google Scholar 

  • Robertson M, Schnieden V, Lees A (1990) Management of Gilles de la Tourette Syndrome using sulpiride. Clin Neuropharmacol 13: 229–235

    PubMed  CAS  Google Scholar 

  • Rossi F, Forgione A (1995) Pharmacotoxicological aspects of levosulpiride. Pharmacol Res 31: 81–94

    PubMed  CAS  Google Scholar 

  • Rüther E, Eben E, Klein H, Nedopil N, Dieterle D, Hippius H (1989) Comparative double-blind study of amisulpride and haloperidol in the treatment of acute episodes of positive schizophrenia. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Française, Paris, pp 63–72

    Google Scholar 

  • Saletu B, Küfferle EB, Grünberger J, Földes P, Topitz A, Anderer P (1994) Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology 29: 125–135

    PubMed  CAS  Google Scholar 

  • Santoni JPH, Saubadu S (1995) Adverse events associated with neuroleptic drugs. Acta Ther 21: 193–204

    CAS  Google Scholar 

  • Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride. JPET 280: 83–97

    CAS  Google Scholar 

  • Smeraldi E (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord 48: 47–56

    PubMed  CAS  Google Scholar 

  • Sokoloff P, Giros B, Martres M, Bouthenet M (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151

    PubMed  CAS  Google Scholar 

  • Standish-Barry H, Bouras N, Bridges P, Watson J (1983) A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology 81: 258–260

    PubMed  CAS  Google Scholar 

  • Sugnaux FR, Benakis A, Fonzo D, Di Carlo R (1983) Dose-dependent pharmacokinetics of sulpiride and sulpiride-induced prolactin secretion in man. Eur J Drug Metabol Pharmacokin 8: 189–190

    CAS  Google Scholar 

  • Toru M, Moriya H, Yammoto K, Shimazono Y (1976) A double blind comparison of sulpiride with chlordiazepoxide in neurosis. Folia Psychiatr Neurol Japon 30: 153–164

    CAS  Google Scholar 

  • Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P (1995) Amisulpride poisoning: a report on two cases. Hum Exp Toxicol 14: 294–298

    PubMed  CAS  Google Scholar 

  • Tridon P (1989) Essai clinique de l’amisulpride en neuropsychiatrie infantile. Neuropsychiatrie de l’Enfance 37: 441–444

    Google Scholar 

  • Vanelle JM, Olié JV, Lévvy-Soussan P (1994) New antipsychotics in schizophrenia: the French experience. Acta Psychiatr Scand 89 [Suppl 380]: 59–63

    Google Scholar 

  • Villari D, Rubino F, Corica F, Spinella S, Di Cesare E, Longo G, Raimondo G (1995) Bile ductopenia following therapy with sulpiride. Virchows Arch 427: 223–226

    PubMed  CAS  Google Scholar 

  • Vivier L ( 1973) A qualitative assessment of the clinical use of new psychotropic preparation — sulpiride. Med Proc 19: 28–30

    Google Scholar 

  • Wiesel FA, Gunnel A, Mats E, Göran S (1982) Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations. Psychopharmacology 76: 44–47

    PubMed  CAS  Google Scholar 

  • Wiesel F, Alfredsson G, Bjierkenstedt L, Härnryd C, Oxenstierna G, Sedvall G (1985) La dogmatil dans le traitement des symptomes negatifs chez des patients schizophrènes. Sem Hôp Paris 61: 1317–1321

    Google Scholar 

  • Yura R, Shibahara Y, Fukushima Y, Sätö M (1976) A double-blind comparative study of the effects of sulpiride and imipramine on depression. Clin Psychiatry 18: 89–92

    Google Scholar 

  • Ziegler B (1989) Study of the efficacy of a substituted benzamide, amisulpride, versus haloperidol, in productive schizophrenia. In: Borenstein P, Boyer P, Braconnier A et al. (eds) Amisulpride. Expansion Scientifique Française, Paris, pp 63–72

    Google Scholar 

Literatur

  • Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788

    PubMed  CAS  Google Scholar 

  • Barnas C, Stuppack CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1991) Zotepin: Die Behandlung schizophrener Patienten mit vorherrschender Negativsymptomatik. Eine Doppelblindstudie vs. Haloperidol. Fortschr Neurol Psychiatr 59 [Suppl 1]: 36–40

    PubMed  Google Scholar 

  • Barnas C, Stuppack CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 7(1): 23–27

    PubMed  CAS  Google Scholar 

  • Dieterle DM, Ackenheil M, Müller-Spahn F, Kapf-Hammer HP (1987) Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 20: 52–57

    PubMed  CAS  Google Scholar 

  • Dieterle DM, Müller-Spahn F, Ackenheil M (1991) Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten. Fortschr Neurol Psychiatr 59 [Suppl 1]: 18–22

    PubMed  Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppack C, Unter-Weger B, Hinterhuber H (1987a) Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 20: 58–60

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Stuppack C, Barnas C, Unter-Weger B, Hinterhuber H (1987b) Low-dose zotepine in the maintenance treatment of schizophrenia. Pharmacopsychiatry 20: 61–63

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Unterweger B, Barnas C, Stuppack C, Hinterhuber H (1987c) Results of an open phase II study with zotepine — a new neuroleptic compound. Pharmacopsychiatry 20: 64–66

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppack CH, Unterweger B, Miller C, Hinterhuber H (1989) Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25(1): 97–100

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppack CH, Sperner-Unterweger B, Miller C, Hinterhuber H (1991) Zotepin vs. Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie. Fortschr Neurol Psychiatr 59 [Suppl 1]: 10–13

    PubMed  Google Scholar 

  • Fujisawa Pharmaceutical Co Ltd (1988) Summary adverse drug reactions in 6-year-post-marke-ting surveillance study of Zotepine (Lodo-pin®) in Japan. Report to the Japanese Ministry of Health and Welfare

    Google Scholar 

  • Haas S (1995) Diskussionsbeitrag. Psychophar-makotherapie 2 [Suppl 3]: 6

    Google Scholar 

  • Hori M, Suzuki T, Sasaki M, Shiraishi H, Koizumi J (1992) Convulsive seizures in schizophrenic patients induced by zotepine administration. Jpn J Psychiatry Neurol 46 (1): 161–167

    PubMed  CAS  Google Scholar 

  • Ishida M (1993) Therapeutic and adverse effects of zotepine and their relationships with serum kinetics of the drug. Yakubutsu Seishin Kodo 13(3): 97–105

    PubMed  CAS  Google Scholar 

  • Klieser E, Lehmann E, Tegeler J (1991) Doppel-blindvergleich von 3 × 75 mg Zotepin und 3 × 4 mg Haloperidol bei akut schizophrenen Patienten. Fortschr Neurol Psychiatr 59 [Suppl 1]: 14–17

    PubMed  Google Scholar 

  • Kondo T, Otani K, Ishida M, Tanaka O, Kaneko S, Fukushima Y (1994) Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 16(2): 120–124

    PubMed  CAS  Google Scholar 

  • Meyer-Lindenberg A, Gruppe H, Bauer U, Krieger S, Lis S, Gallhofer B (1997) Improvement of cognitive functioning in schizophrenic patients receiving zotepine or clozapine: results of a double-blind trial. Pharmacopsychiatry 30: 35–42

    PubMed  CAS  Google Scholar 

  • Müller WE (1994) Rezeptorbindungsprofil von Zotepin. Nervenarzt 65(7) Beilage

    Google Scholar 

  • Otani K, Hirano T, Kondo T, Kaneko S, Fukushima Y, Noda K, Tashiro Y (1990) Biperiden and piroheptine do not affect the serum level of zotepine, a new antipsychotic drug. Br J Psychiatry 157: 128–130

    PubMed  CAS  Google Scholar 

  • Otani K, Kondo T, Kaneko S, Ishida M, Fukushima Y (1994) Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. Int Clin Psychopharmacol 9(4): 287–289

    PubMed  CAS  Google Scholar 

  • Overall JE, Gorham DR (1962) Brief psychiatric rating scale. Psychol Rep 10: 799–812

    Google Scholar 

  • Rhone-Poulenc Rorer GMBH (1995) Produktmonographie Nipolept. Rhone Poulenc Rorer GmbH Firmenverlag

    Google Scholar 

  • Wetterling T, Müssigbrodt H (1996) Gewichtszunahme: eine Nebenwirkung von Zotepin (Nipolept®)? Nervenarzt 67: 256–261

    PubMed  CAS  Google Scholar 

  • Wetzel H, von Bardeleben U, Holsboer F, Benkert O (1991) Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppel-blind-kontrollierte Wirksamkeitsprüfung. Fortschr Neurol Psychiatr 59 [Suppl 1]: 23–29

    PubMed  Google Scholar 

  • Wolfersdorf M, Konig F, Straub R (1994) Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology 29(4): 189–193

    PubMed  CAS  Google Scholar 

  • Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I (1995) Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 28(2): 56–60

    PubMed  CAS  Google Scholar 

Literatur

  • Beasley CM, Sanger TM, Satterlee W, Tollefson GD et al. (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124: 159–167

    PubMed  CAS  Google Scholar 

  • Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, The Olanzapine Hgad Study Group (1996) Olanzapine versus placebo and haloperidol. Neuropsychopharmacol 14: 111–123

    CAS  Google Scholar 

  • Borison RL, Arvanitis LA, Miller BG, Seroquel Study Group (1996) ICI 204.636, an atypical antipsychotic: efficacy and safety in a multi-center, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158–169

    PubMed  CAS  Google Scholar 

  • Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong TD (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 14: 87–96

    CAS  Google Scholar 

  • Casey DE (1996) „Seroquel“ (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5: 939–957

    CAS  Google Scholar 

  • Dunn CJ, Fitton A (1996) Sertindole. CNS Drugs 5: 224–230

    CAS  Google Scholar 

  • Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB (1995) Seroquel™ (ICI 204,636), a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 17: 366–378

    PubMed  Google Scholar 

  • Fleischhacker WW, Link CGG, Horne B (1995) A multicentre, double-blind, randomized comparison of dose and dose regimes of Seroquel™ in the treatment of patients with schizophrenia. Poster presented at the 34th ACNP Meeting, San Juan, December 11–15, 1995

    Google Scholar 

  • Fulton B, Goa KL (1995) ICI-204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 4: 68–78

    Google Scholar 

  • Gefvert O, Lindstrom LH, Langstrom B, Bergstrom M, Lundberg T, Yates RA, Larsson SD, Tuersley MD (1995) Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel™ tid. Eur Neuropsychopharmacol 5: 347

    Google Scholar 

  • Goldstein JM (1995) Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 4: 291–298

    CAS  Google Scholar 

  • Goldstein JM, Arvanitis LA (1995) ICI 204,636 (Seroquel™): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1: 50–73

    CAS  Google Scholar 

  • Goldstein JM, Arvanitis LA (1997) „Seroquel“ (Quetiapine), a promising new antipsychotic agent: overview of safety and tolerability. Poster presented at the APA Annual Meeting. San Diego, May 17–22, 1997

    Google Scholar 

  • Hale A, van der Burght M, Wehnert A, Friberg HH (1996) A European dose-range study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose of haloperidol in schizophrenic patients. Poster presented at the XXth CINP Congress, June 23–27, 1996, Melbourne

    Google Scholar 

  • Hirsch S, Link CG, Goldstein JM, Arvanitis LA (1996) ICI 20,636: a new atypical antipsychotic drug. Br J Psychiatry 168 [Suppl 29]: 45–56

    Google Scholar 

  • Hummer M, Kurz M, Kohl C, Walch T, Fleisch-Hacker WW (1997) Selection bias in clinical trials with antipsychotics. Schizophr Res 24: 207

    Google Scholar 

  • Link C, Arvanitis L, Miller B, Fennimore J (1994) A multicenter, double-blind, placebocontrol-led, evaluation of Seroquel™ in hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. Poster presented at the VIIth Congress of the European College of Neuropsychopharmacology, October 16–21, 1994, Jerusalem

    Google Scholar 

  • Möller HJ (1995) The negative component in schizophrenia. Acta Psychiatr Scand 91 [Suppl 388]: 11–14

    Google Scholar 

  • Robertson GS, Fibiger C (1996) Effects of olanzapine on regional C-Fos expression in rat fore-brain. Neuropsychopharmacology 14:105–110

    PubMed  CAS  Google Scholar 

  • Robinson D, Woerner MG, Pollack S, Lerner G (1996) Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol 16: 170–176

    PubMed  CAS  Google Scholar 

  • Saller FC, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112: 285–292

    PubMed  CAS  Google Scholar 

  • Seroquel (1995)A putative atypical antipsychotic drug with serotonin-and dopamine-receptor antagonist properties. J Clin Psychiatry 56: 438–445

    Google Scholar 

  • Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289–294

    PubMed  CAS  Google Scholar 

  • Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacol 14: 97–104

    CAS  Google Scholar 

  • Tollefson GD, Beaslfy CM, Tran PU, Street JS, Krueger JA, Tamira RN, Graffeo KA, Thieme ME (1997) Olanzapine vs haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457–465

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Sanger TM, Beasley CM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466–474

    PubMed  CAS  Google Scholar 

  • Van Kammen DP, Mcevoy JP, Targum SD, Kar-Datzke D, Sebree T, Sertindole Study Group (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168–175

    PubMed  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak TJ, Sebree TB, Wallin BA, Kashkin KB, Sertindole Study Group (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791

    PubMed  CAS  Google Scholar 

Literatur

  • Flaim SF, Brannan MD, Surgart SC, Gleason MM, Muschek LD (1985) Neuroleptic drugs attenuate calcium influx and tension development in rabbit thoracic aorta: effects of pimozide, penfluridol, chlorpromazine, and haloperidol. Proc Natl Acad Sci USA 82: 1237–1241

    PubMed  CAS  Google Scholar 

  • Gaebel W (1993) Perazin — ein klassisches Neu-roleptikum aus der Gruppe der piperazin-substituierten Phenothiazine. Fundam Psychiatr 7: 48–57

    Google Scholar 

  • Gould RJ, Murphy KMM, Reynolds IJ, Snyder SH (1983) Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 80: 5122–5125

    PubMed  CAS  Google Scholar 

  • Janssen PAJ, Awouters FHC (1994) Is it possible to predict clinical effect of neuroleptics from animal data? Part V. Arzneimittelforschung 44: 269–277

    CAS  Google Scholar 

  • Klages U, Hippies H, Müller-Spahn F (1993) Atypische Neuroleptika, Pharmakologie und klinische Bedeutung. Fortschr Neurol Psychiatr 61: 390–398

    PubMed  CAS  Google Scholar 

  • Leysen JE, Janssen PAJ, Schotte A, Luvten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112: S40–S54

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine d-1, d-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238–251

    PubMed  CAS  Google Scholar 

  • Möller HJ (1995) Neuere Aspekte in der Diagnostik und Behandlung der Negativsymptomatik schizophrener Patienten. In: Hinterhuber H, Fleischhacker WW, Meise U (Hrsg) Die Behandlung der Schizophrenien — State of the Art. Verlag Integrative Psychiatrie, Innsbruck Wien, S 197–212

    Google Scholar 

  • Müller WE (1990) Pharmakologische Aspekte der Neuroleptikawirkung. In: Heinrich K (Hrsg) Leitlinien neuroleptischer Therapie. Springer, Berlin Heidelberg New York Tokyo, S 3–23

    Google Scholar 

  • Müller WE (1991) Wirkungsmechanismus niedrigdosierter Neuroleptika bei Angst und Depression. In: Pöldinger W (Hrsg) Niedrigdosierte Neuroleptika bei ängstlich-depressiven Zustandsbildern und psychosomatischen Erkrankungen. Braun, Karlsruhe, S 24–38

    Google Scholar 

  • Müller WE, Tuschl R, Gietzen K ( 1995) Therapeutische und unerwünschte Wirkungen von Neuroleptika — die Bedeutung von Rezeptorprofilen. Psychopharmakotherapie 2: 148–153

    Google Scholar 

  • Robertson MM, Trimble MR (1982) Major tranquilizers used as antidepressants. J Affect Disord 4: 173–193

    PubMed  CAS  Google Scholar 

  • Snyder SH, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. Gallhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Meyer-Lindenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Broich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. E. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Naber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Müller-Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H.-J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. W. Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Wien

About this chapter

Cite this chapter

Gallhofer, B. et al. (1998). (Sogenannte) Atypische Neuroleptika (Antipsychotika). In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6458-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6458-7_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7327-5

  • Online ISBN: 978-3-7091-6458-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation